✦ LIBER ✦

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

✍ Scribed by Ruzsa, A.; Sen, M.; Evans, M.; Lee, L. W.; Hideghety, K.; Rottey, S.; Klimak, P.; Holeckova, P.; Fayette, J.; Csoszi, T.; Erfan, J.; Forssmann, U.; Goddemeier, T.; Bexon, A.; Nutting, C.

Book ID: 125358957
Publisher: Springer US
Year: 2014
Tongue: English
Weight: 487 KB
Volume: 32
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-014-0117-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

8585 POSTER Efficacy of Cetuximab Alone

8585 POSTER Efficacy of Cetuximab Alone or in Combination With Docetaxel as Second-line Treatment in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)

✍ Fekih, M.; Ferrand, F.R.; Saada, E.; Hamdan, D.; Desmaris, R.; Schilf, A.; Guiga 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Phase 1b Trial of TLR8 Agonist VTX-2337

Phase 1b Trial of TLR8 Agonist VTX-2337 in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)

✍ Chow, L.Q.M.; Eaton, K.D.; Baik, C.; Goulart, B.; Morishima, C.; Disis, M.L.; Ma 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 74 KB

5501 ORAL Cetuximab plus platinum-based

5501 ORAL Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME)

✍ Vermorken, J.B.; Hitt, R.; Geoffrois, L.; Erfan, J.; Kawecki, A.; Zabolotnyy, D. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

97 Phase I study of cetuximab (C225)in c

97 Phase I study of cetuximab (C225)in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN)

✍ J. Bourhis; F. Rivera; R. Mesia; A. Awada; L. Geoffrois; C. Borel; L. Duck; E. B 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 154 KB

8517 Phase I results from an open-label,

8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)

✍ Brümmendorf, T.; Guigay, J.; Mesía, R.; Trigo, J.; Keilholz, U.; Dittrich, C.; K 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 72 KB

8519 A phase 2, randomized trial (CONCER

8519 A phase 2, randomized trial (CONCERT-1) of chemoradiotherapy with or without panitumumab in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Interim pooled safety analysis

✍ Fortin, A.; Cmelak, A.; Mesía, R.; Minn, H.; Chan, A.T.C.; Yunes, A.C.; Merlano, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB